Medicine and Health Sciences Commons^™

Covid-19: The Vaccine Race Continues, L. Hayley Burgess, Carley Castelein, Andrew Rubio, Mandelin K. Cooper

HCA Healthcare Journal of Medicine

Over a year has passed since the discovery of SARS-CoV-2 and the subsequent COVID-19 pandemic. As mitigation efforts continue, COVID-19 has claimed over half a million lives in the United States and 3.1 million lives globally. The development and availability of vaccines delivering immunity to prevent COVID-19 offers hope to end the pandemic.

Emergency use authorizations from the Food and Drug Administration have been issued in the United States for three vaccines, one each from Pfizer-BioNTech, Moderna and Janssen/J&J. Pfizer-BioNTech and Moderna are both mRNA vaccines with efficacy of 95% and 94.1% respectively, while the vector-based vaccine from Janssen/J&J has …

A Data Driven Approach To Profile Potential Sars-Cov-2 Drug Interactions Using Tylerade, Robert P. Schumaker, Michael A. Veronin, Trevor Rohm, Matthew Boyett, Rohit R. Dixit

Journal of International Technology and Information Management

We use a data driven approach on a cleaned adverse drug reaction database to determine the reaction severity of several covid-19 drug combinations currently under investigation. We further examine their safety for vulnerable populations such as individuals 65 years and older. Our key findings include 1. hydroxychloroquine/chloroquine are associated with increased adverse drug event severity versus other drug combinations already not recommended by NIH treatment guidelines, 2. hydroxychloroquine/azithromycin are associated with lower adverse drug event severity among older populations, 3. lopinavir/ritonavir had lower adverse reaction severity among toddlers and 4. the combination of azithromycin, hydroxychloroquine and tocilizumab is safer than …